Wall Street analysts expect Mylan (NASDAQ:MYL) to report $3.29 billion in sales for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for Mylan’s earnings, with the highest sales estimate coming in at $3.38 billion and the lowest estimate coming in at $3.19 billion. Mylan reported sales of $3.27 billion in the same quarter last year, which indicates a positive year over year growth rate of 0.6%. The business is scheduled to report its next quarterly earnings results on Wednesday, March 7th.

On average, analysts expect that Mylan will report full-year sales of $3.29 billion for the current fiscal year, with estimates ranging from $11.86 billion to $12.05 billion. For the next fiscal year, analysts forecast that the business will post sales of $12.62 billion per share, with estimates ranging from $12.28 billion to $13.18 billion. Zacks’ sales averages are a mean average based on a survey of analysts that that provide coverage for Mylan.

Mylan (NASDAQ:MYL) last issued its quarterly earnings data on Monday, November 6th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.20 by ($0.10). The firm had revenue of $2.99 billion for the quarter, compared to analysts’ expectations of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. The firm’s revenue was down 2.3% on a year-over-year basis. During the same period last year, the company earned $1.38 earnings per share.

Several research firms recently weighed in on MYL. Citigroup restated a “buy” rating and set a $58.00 price target (up previously from $48.00) on shares of Mylan in a report on Thursday. Leerink Swann began coverage on Mylan in a report on Tuesday. They set a “market perform” rating and a $44.00 price target on the stock. Cantor Fitzgerald set a $41.00 price target on Mylan and gave the company a “hold” rating in a report on Tuesday, December 26th. BidaskClub upgraded Mylan from a “buy” rating to a “strong-buy” rating in a report on Tuesday, December 19th. Finally, Guggenheim began coverage on Mylan in a report on Tuesday, December 12th. They set a “buy” rating and a $59.00 price target on the stock. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $43.20.

Hedge funds have recently added to or reduced their stakes in the business. Suntrust Banks Inc. grew its position in shares of Mylan by 0.7% during the 2nd quarter. Suntrust Banks Inc. now owns 9,184 shares of the company’s stock worth $355,000 after buying an additional 60 shares in the last quarter. Dai Ichi Life Insurance Company Ltd grew its position in shares of Mylan by 0.4% during the 2nd quarter. Dai Ichi Life Insurance Company Ltd now owns 26,002 shares of the company’s stock worth $1,009,000 after buying an additional 107 shares in the last quarter. Wealthsource Partners LLC grew its position in shares of Mylan by 1.9% during the 2nd quarter. Wealthsource Partners LLC now owns 9,330 shares of the company’s stock worth $362,000 after buying an additional 177 shares in the last quarter. Accident Compensation Corp grew its position in shares of Mylan by 0.3% during the 2nd quarter. Accident Compensation Corp now owns 71,035 shares of the company’s stock worth $2,758,000 after buying an additional 200 shares in the last quarter. Finally, Riverhead Capital Management LLC grew its position in shares of Mylan by 4.8% during the 2nd quarter. Riverhead Capital Management LLC now owns 7,196 shares of the company’s stock worth $279,000 after buying an additional 328 shares in the last quarter. Institutional investors and hedge funds own 74.90% of the company’s stock.

Shares of Mylan (MYL) traded up $0.23 on Wednesday, hitting $44.54. The stock had a trading volume of 5,325,200 shares, compared to its average volume of 6,630,000. The stock has a market cap of $23,770.00, a PE ratio of 26.83, a price-to-earnings-growth ratio of 1.44 and a beta of 1.38. Mylan has a twelve month low of $29.39 and a twelve month high of $45.87. The company has a quick ratio of 0.95, a current ratio of 1.46 and a debt-to-equity ratio of 1.05.

ILLEGAL ACTIVITY NOTICE: This piece was originally posted by Marea Informative and is owned by of Marea Informative. If you are reading this piece on another publication, it was copied illegally and republished in violation of US & international copyright and trademark laws. The legal version of this piece can be read at https://www.mareainformativa.com/2018/01/29/mylan-myl-expected-to-post-quarterly-sales-of-3-29-billion-updated-updated-updated.html.

Mylan Company Profile

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Get a free copy of the Zacks research report on Mylan (MYL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.